Literature DB >> 17452254

MLL amplification in acute myeloid leukemia.

Juan C Pajuelo-Gámez1, José Cervera, Zaida García-Casado, Armando V Mena-Durán, Ana Valencia, Eva Barragán, Esperanza Such, Pascual Bolufer, Miguel A Sanz.   

Abstract

The chromosomal alterations at 11q23 that involve the mixed-lineage leukemia gene (MLL, HTRX1, HRX, ALL1) are one of the most common cytogenetic abnormalities in acute leukemia and have been associated with a poor prognosis. Given that not all MLL alterations are seen under conventional cytogenetics or fluorescence in situ hybridization (FISH), it is very important to use molecular techniques to determine the cause of alteration. In this study, we describe two cases of AML in which FISH analysis showed a high-level 11q23 amplification, to confirm if this overexpression may be accompanied by partial tandem duplication of the MLL gene (MLL-PTD). Both patients showed complex karyotype and an unfavorable clinical course. The 11q23 region characterization included conventional cytogenetics, FISH, and comparative genomic hybridization analysis to study the expression patterns of several oncogenes located within the amplified region and detection of partial tandem duplication of the MLL gene by reverse-transcription polymerase chain reaction (RT-PCR) and sequencing. MLL-PTD were detected in the two patients. Moreover, patient 1 showed amplification of the MLL flanking region. Our data suggest that molecular methods such as RT-PCR or sequencing should be used to detect MLL alterations, and that amplification of MLL locus may be extended to its flanking region.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452254     DOI: 10.1016/j.cancergencyto.2006.11.019

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  1 in total

1.  Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia.

Authors:  Bon Ham Yip; Chiou Tsun Tsai; Jayant K Rane; Winston Vetharoy; Eduardo Anguita; Shuo Dong; Michael A Caligiuri; Chi Wai Eric So
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.